MedTrace Logo

Safety and Durability of Sirolimus for Treatment of LAM

NCT02432560 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-12-24

No results posted yet for this study

Summary

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Conditions

  • Lymphangioleiomyomatosis

Interventions

DRUG

Sirolimus

Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.

DRUG

Everolimus

Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.

Sponsors & Collaborators

  • Rare Diseases Clinical Research Network

    collaborator NETWORK

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • The LAM Foundation

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Francis X McCormack, MD · University of Cincinnati

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432560 on ClinicalTrials.gov